Campbell, R Keith <br/><br/>
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.  [electronic resource] 

 -  The Journal of family practice  Sep 2010 
 - S5-9 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article 
<br/><br/><label>ISSN: </label>1533-7294 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adamantane--analogs & derivatives<br/>Aged<br/>Blood Glucose<br/>Diabetes Mellitus, Type 2--drug therapy<br/>Dipeptides--therapeutic use<br/>Exenatide<br/>Female<br/>Glucagon--metabolism<br/>Glucagon-Like Peptide 1--analogs & derivatives<br/>Humans<br/>Hypoglycemic Agents--therapeutic use<br/>Incretins--therapeutic use<br/>Insulin-Secreting Cells--physiology<br/>Liraglutide<br/>Male<br/>Metformin--therapeutic use<br/>Middle Aged<br/>Peptides--therapeutic use<br/>Pyrazines--therapeutic use<br/>Severity of Illness Index<br/>Sitagliptin Phosphate<br/>Time Factors<br/>Triazoles--therapeutic use<br/>Venoms--therapeutic use